Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XNW5004 + enzalutamide
- Development stage
- Unknown
- Lead developer
- Evopoint Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**XNW5004 + enzalutamide** is an investigational combination therapy for cancer, specifically studied in metastatic castration-resistant prostate cancer (mCRPC). **XNW5004** is a substrate-competitive, selective, small-molecule inhibitor of **EZH2** (Enhancer of Zeste Homolog 2), developed by Evopoint, with demonstrated anti-tumor efficacy in lymphoma and manageable safety profile[1][3][5]. **Enzalutamide** is a second-generation androgen receptor (AR) inhibitor approved for various prostate cancer indications, working by blocking the androgen receptor and thereby inhibiting testosterone-driven cancer cell growth[2][6][8]. The combination is being tested to overcome drug resistance and improve progression-free survival in mCRPC, especially after novel hormonal therapy failure[1][3][7][9].
- Other names
- XNW 5004XNW5004XNW-5004MDV3100MDV-3100MDV 3100Enzalutamida
02
Targets
AR (Adrenergic receptors)EZH2 (Histone-lysine N-methyltransferase EZH2)
Beyond the preview
Go deeper on XNW5004 + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XNW5004 + enzalutamide.